InMode combines a peer-relative value discount and a strong 3-of-4 earnings beat streak heading into a near-term catalyst with a negative asymmetry setup at an already-reached price target and an earnings-quality warning.
Thesis pillars
- Peer Relative Value Strength→Stable
- Earnings Quality Warning→Stable
- Elevated Options Pricing Above Max Pain↑Improving
- +2 more pillars — see the Why tab for full reasoning
InMode Ltd. (INMD) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $15.10 — A.R:R is negative (-2.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk).
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.... Read more
Sell if holding. Analyst target reached at $15.10 — A.R:R is negative (-2.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk). Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 5/9 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Recent developments
updated 2026-07-24Recent Developments — InMode Ltd.
Latest news
- NEWS Steel Partners Questions Management Steering Results To Fit CEO’s Lowball Bid And Calls Board To Reschedule AGM — benzinga Jul 16, 2026 negative
- NEWS InMode Reports Preliminary Q2 Sales Of $95.2M-$95.4M; Reaffirms FY2026 Sales Guidance Of $365M-$375M — benzinga Jul 13, 2026 positive
- NEWS InMode Confirms Receipt Of Unsolicited Letter And Acquisition Proposal From Steel Partners; Financial Terms Not Disclose — benzinga Jul 10, 2026 negative
- NEWS Steel Partners Offers $16.75 Per Share To Acquire InMode, Urges Board To Reject CEO-Led Bid — benzinga Jul 9, 2026 negative
Generated 2026-07-25T09:22:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $15.10 — A.R:R is negative (-2.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk). Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $14.45. Score 5.5/10, moderate confidence.
Take-profit target: $15.36 (-13.6% upside). Prior stop was $14.45. Stop-loss: $14.45.
Analyst target reached - limited upside remaining; Earnings in 5 days (event risk); Weak growth.
InMode Ltd. trades at a P/E of 11.3 (forward 10.4). TrendMatrix value score: 7.1/10. Verdict: Sell.
12 analysts cover INMD with a consensus score of 3.8/5. Average price target: $15.
What does InMode Ltd. do?InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its...
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.